Lilly's targeted RET drug shrinks tumors in lung cancer trial [Reuters]
Blueprint Medicines Corporation (BPMC)
Last blueprint medicines corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
blueprintmedicines.com
Company Research
Source: Reuters
Lilly's targeted RET drug shrinks tumors in lung cancer trial (Reuters) - Eli Lilly and Co’s LOXO-292, a experimental cancer drug the company acquired in January as part of its $8 billion takeover of Loxo Oncology, shrank tumors in nearly 70% of advanced lung cancer patients whose tumors carried specific abnormalities in the RET gene. The results, presented on Monday at the Lung Conference on Lung Cancer in Barcelona, will support Lilly’s application for U.S. Food and Drug Administration approval later this year. “At the beginning of this year, we put a bet on Loxo,” Dr. Daniel Skovronsky, Lilly’s chief scientific officer, said in a telephone interview. “The result today certainly validates that bet and exceeds what many people expected.” Lilly’s drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2% of non-small cell lung cancers, some 10 to 20% of papillary thyroid cancers and about 60% of medullary thyroid cancers. The study r
Show less
Read more
Impact Snapshot
Event Time:
BPMC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BPMC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BPMC alerts
High impacting Blueprint Medicines Corporation news events
Weekly update
A roundup of the hottest topics
BPMC
News
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Citigroup Inc. from $65.00 to $76.00. They now have a "sell" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at JMP Securities from $114.00 to $125.00. They now have a "market outperform" rating on the stock.MarketBeat
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at HC Wainwright from $125.00 to $135.00. They now have a "buy" rating on the stock.MarketBeat
- Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises [Yahoo! Finance]Yahoo! Finance
- Blueprint Medicines Co. (NASDAQ: BPMC) had its price target raised by analysts at Barclays PLC from $70.00 to $75.00. They now have an "equal weight" rating on the stock.MarketBeat
BPMC
Earnings
- 5/2/24 - Beat
BPMC
Sec Filings
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 144
- 5/2/24 - Form 144
- BPMC's page on the SEC website